Question for the science guys that I don't think I've seen asked yet (if I missed it please just direct me to the post with the explanation). Our 5 survivors were treated with LL and an ICI. Of the 5 though, 4 were treated with Atezolizumabin, which showed little to no efficacy in their Phase 3 trial for mTNBC and led to the drug being discontinued by Roche before the FDA revoked their conditional approval. So, my question is, if Atezolizumabin was proven to be ineffective in mTNBC, did this ICI actually become effective because of LL or did this ICI do nothing like it did in its Phase 3 trial and it was all LL? If it's the latter, would that mean that the 5th patient who took Keytruda could have not benefitted from Keytruda at all and it was all LL.